204 related articles for article (PubMed ID: 12166031)
1. Natural product drug discovery and development: the United States National Cancer Institute role.
Cragg GM
P R Health Sci J; 2002 Jun; 21(2):97-111. PubMed ID: 12166031
[No Abstract] [Full Text] [Related]
2. Historical background of the National Cancer Institute's drug development thrust.
Zubrod CG; Schepartz SA; Carter SK
Natl Cancer Inst Monogr; 1977 Mar; (45):7-11. PubMed ID: 337156
[No Abstract] [Full Text] [Related]
3. Natural products in drug discovery--organizing for success.
McChesney JD
P R Health Sci J; 2002 Jun; 21(2):91-5. PubMed ID: 12166030
[No Abstract] [Full Text] [Related]
4. The NCI Developmental Therapeutics Program.
Collins JM
Clin Adv Hematol Oncol; 2006 Apr; 4(4):271-3. PubMed ID: 16728938
[No Abstract] [Full Text] [Related]
5. History of the National Cancer Institute and the plant screening program.
Schepartz SA
Cancer Treat Rep; 1976 Aug; 60(8):975-7. PubMed ID: 791487
[No Abstract] [Full Text] [Related]
6. Anticancer drug development at the US National Cancer Institute.
Takimoto CH
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S29-33. PubMed ID: 12819935
[TBL] [Abstract][Full Text] [Related]
7. Origins and development of chemotherapy research at the National Cancer Institute.
Zubrod CG
Cancer Treat Rep; 1984 Jan; 68(1):9-19. PubMed ID: 6362871
[No Abstract] [Full Text] [Related]
8. As memory serves--an informal history of the National Cancer Institute, 1937-57.
Shimkin MB
J Natl Cancer Inst; 1977 Aug; 59(2 Suppl):559-600. PubMed ID: 328903
[No Abstract] [Full Text] [Related]
9. Screening at the National Cancer Institute.
Goldin A; Venditti JM; Carter SK
Natl Cancer Inst Monogr; 1977 Mar; (45):37-48. PubMed ID: 337155
[No Abstract] [Full Text] [Related]
10. Lost colony: Laboratory of Experimental Oncology, San Francisco, 1947--54: historical note.
Shimkin MB
J Natl Cancer Inst; 1978 Feb; 60(2):479-88. PubMed ID: 340707
[No Abstract] [Full Text] [Related]
11. The evaluation of cytotoxic drugs.
Von Hoff DD; Rozencweig M; Muggia FM
Cancer Treat Rev; 1979 Jun; 6 Suppl():1-8. PubMed ID: 498161
[No Abstract] [Full Text] [Related]
12. Clinical development of anticancer agents--a National Cancer Institute perspective.
Marsoni S; Wittes R
Cancer Treat Rep; 1984 Jan; 68(1):77-85. PubMed ID: 6362870
[No Abstract] [Full Text] [Related]
13. The linear array.
Zubrod CG; Schepartz SA; Carter SK
Natl Cancer Inst Monogr; 1977 Mar; (45):13-4. PubMed ID: 927488
[No Abstract] [Full Text] [Related]
14. The National Cancer Institute: cancer drug discovery and development program.
Grever MR; Schepartz SA; Chabner BA
Semin Oncol; 1992 Dec; 19(6):622-38. PubMed ID: 1462164
[TBL] [Abstract][Full Text] [Related]
15. In the middle: 1954---63--historical note.
Shimkin MB
J Natl Cancer Inst; 1979 May; 62(5):1295-317. PubMed ID: 220451
[No Abstract] [Full Text] [Related]
16. Experimental evaluation of antitumor drugs in the USA and USSR and clinical correlations.
Natl Cancer Inst Monogr; 1980 Dec; (55):1-179. PubMed ID: 7010179
[No Abstract] [Full Text] [Related]
17. History of the Cancer Chemotherapy Program.
Cancer Chemother Rep; 1966 Oct; 50(7):349-96. PubMed ID: 5331634
[No Abstract] [Full Text] [Related]
18. The NCI60 human tumour cell line anticancer drug screen.
Shoemaker RH
Nat Rev Cancer; 2006 Oct; 6(10):813-23. PubMed ID: 16990858
[TBL] [Abstract][Full Text] [Related]
19. Proceedings: National Cancer Institute: an overview with historic footnotes; a report on the U.S.-U.S.S.R. health agreement.
Bruno AM
Natl Cancer Inst Monogr; 1974 Feb; 40():7-20. PubMed ID: 4594641
[No Abstract] [Full Text] [Related]
20. "Who will bell the cat?" Andrew C. Ivy and Krebiozen.
Ward PS
Bull Hist Med; 1984; 58(1):28-52. PubMed ID: 6370345
[No Abstract] [Full Text] [Related]
[Next] [New Search]
